---
title: "GILD.US (GILD.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/GILD.US/news.md"
symbol: "GILD.US"
name: "GILD.US"
parent: "https://longbridge.com/en/quote/GILD.US.md"
datetime: "2026-05-19T22:55:22.180Z"
locales:
  - [en](https://longbridge.com/en/quote/GILD.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/GILD.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/GILD.US/news.md)
---

# GILD.US (GILD.US) — Related News

### [Daiwa Securities Group Issues Pessimistic Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price](https://longbridge.com/en/news/286931846.md)
*2026-05-19T14:35:30.000Z*
> Daiwa Securities Group has lowered its target price for Gilead Sciences (NASDAQ:GILD) from $161.00 to $150.00 while main

### [ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/286893590.md)
*2026-05-19T10:19:31.000Z*
> ProShare Advisors LLC increased its stake in Gilead Sciences, Inc. by 39.1% in Q4, acquiring 623,752 shares, bringing it

### [Gilead Sciences is mired in the CAR-T quagmire](https://longbridge.com/en/news/286828648.md)
*2026-05-18T23:33:04.000Z*
> Gilead's investment in the CAR-T field has failed to achieve profitability, instead falling into a cycle of continuous i

### [Compugen Q1 Earnings Call Highlights](https://longbridge.com/en/news/286785249.md)
*2026-05-18T14:08:24.000Z*
> Compugen (NASDAQ:CGEN) is on track to report interim progression-free survival data from its MAIA-ovarian study in Q1 20

### [Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline](https://longbridge.com/en/news/286673327.md)
*2026-05-17T13:03:32.000Z*
> Gilead Sciences is focusing on its HIV business while expanding its oncology and inflammation pipelines through recent a

### [A Look At Gilead Sciences (GILD) Valuation After The Recent Share Price Pullback](https://longbridge.com/en/news/286642315.md)
*2026-05-16T10:14:27.000Z*
> Gilead Sciences (GILD) has experienced a stock pullback of 7% in the past month and 16% over three months, despite a 30%

### [Gilead Sciences Inc. Stock Underperforms Friday When Compared To Competitors](https://longbridge.com/en/news/286611724.md)
*2026-05-15T20:35:25.000Z*
> Gilead Sciences Inc. (GILD) shares fell 1.88% to $129.58 on Friday, marking the third consecutive day of losses. The sto

### [Gilead Sciences prices $3B multi-tranche senior notes offering](https://longbridge.com/en/news/286518399.md)
*2026-05-15T06:31:18.000Z*
> Gilead Sciences (GILD) has priced a public offering of senior unsecured notes totaling $3B. This includes $500M of 4.250

### [Gilead Prices $3 Billion of Senior Unsecured Notes | GILD Stock News](https://longbridge.com/en/news/286490178.md)
*2026-05-14T17:25:30.000Z*
> Gilead Prices $3 Billion of Senior Unsecured Notes | GILD Stock News